You are in: eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease PharyngitisArticle Last Updated: Nov 24, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Harold K Simon, MD, MBA, Professor of Pediatrics and Emergency Medicine, Associate Division Director of Pediatric Emergency Medicine, Director of Research, Division of Pediatric Emergency Medicine, Emory University School of Medicine, Children's Healthcare of Atlanta at Egleston Harold K Simon is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, Sigma Xi, and Society for Academic Emergency Medicine Editors: Rosemary Johann-Liang, MD, Medical Officer, Infectious Diseases and Pediatrics, Division of Special Pathogens and Immunological Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine; Leslie L Barton, MD, Professor, Program Director, Department of Pediatrics, University of Arizona School of Medicine; Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine; Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine Author and Editor Disclosure Synonyms and related keywords: pharyngitis, sore throat, tonsillitis, tonsillopharyngitis, nasopharyngitis, pharyngeal inflammation, group A beta-hemolytic streptococci, GABHS, GABHS pharyngitis, viral pharyngitis, rheumatic fever, rhinorrhea, laryngitis, adenoviruses, enteroviruses, Epstein-Barr virus, EBV, Staphylococcus aureus, Haemophilus influenzae, Branhamella catarrhalis, Bacteroides fragilis, Bacteroides oralis, Bacteroides melaninogenicus, Fusobacterium species, Peptostreptococcus species, Chlamydia trachomatis, Mycoplasma pneumoniae, diphtheria, conjunctivitis, coryza, herpangina, hand-foot-and-mouth disease INTRODUCTIONBackgroundPharyngitis is a leading cause of pediatric ambulatory care visits. Examination of patients who present with sore throat may reveal tonsillitis, tonsillopharyngitis, or nasopharyngitis. The absence of pharyngeal inflammation or the presence of either rhinorrhea or laryngitis is much more likely to be associated with viral infection. However, no physical findings clearly separate group A beta-hemolytic streptococci (GABHS) from viral, other bacterial, or noninfectious causes. The primary concern for pharyngitis in children aged 3-18 years is that untreated GABHS may subsequently cause rheumatic fever. To prevent this sequela, institute adequate antimicrobial therapy within 9 days of infection. Rapid antigen detection assays for GABHS are diagnostic if positive because the specificity of such tests is 98-99% (ie, 1-2% false-positive results); however, sensitivity is only 70% (ie, 30% false-negative results), requiring follow-up cultures for negative results. The drug of choice to treat group A streptococci remains penicillin V, although many experts recommend a higher dosage than was used in the past. Other bacteria that occasionally cause pharyngitis and require antimicrobial therapy include gonococcus; Francisella tularensis; groups B, C, and G streptococci; Arcanobacterium hemolyticum; and Treponema pallidum. No treatment is of any benefit for the usual viral causes of pharyngitis. Discourage the use of throat lozenges, sprays, mouthwashes, decongestants, and antihistamines. PathophysiologyMultiple etiologies can cause irritation and inflammation of the pharynx. Causes in children range from viruses (eg, adenoviruses, enteroviruses, Epstein-Barr virus [EBV]), which often require only supportive therapy, to bacterial pathogens (eg, GABHS), which require antibiotic therapy. GABHS pharyngitis is spread via respiratory droplets through close contact. No pathogen is isolated in nearly 30% of cases, and viruses are isolated in approximately 40% of cases. Other probable copathogens in children include Staphylococcus aureus, Haemophilus influenzae, Branhamella catarrhalis, Bacteroides fragilis, Bacteroides oralis, Bacteroides melaninogenicus, Fusobacterium species, and Peptostreptococcus species. Less common causes include Chlamydia trachomatis and Mycoplasma pneumoniae. GABHS is the primary organism of concern in most pediatric cases of pharyngitis because appropriate antibiotic therapy is effective and can eliminate complications of rheumatic heart disease. For all cases, including viral etiologies, supportive care is necessary to prevent associated symptoms such as dehydration. FrequencyUnited StatesApproximately 10% of children seen by medical care providers each year have pharyngitis, and 25-50% of these children have GABHS. Approximately 20% of asymptomatic children are chronic carriers of GABHS. InternationalThe entire range of pharyngitis-causing pathogens is observed throughout the world. Certain pathogens that are virtually nonexistent in the United States cause pharyngitis in other areas. A good example is diphtheria, which has been nearly eradicated in the United States through immunizations. According to the Red Book, from 1990-1995, approximately 48,000 cases of epidemic diphtheria were reported in the former Soviet Union and central Asia.1 Given the high case-fatality rate of 3-23% and the increased mobility of people, the potential for worldwide spread of diphtheria is a cause for concern. Consider rare or unsuspected causative agents in afflicted individuals who have traveled to high-risk areas or for individuals who have emigrated from these regions, especially in nonimmunized patients. RacePrevalence is equal among all races. AgePeak prevalence of GABHS pharyngitis is in children aged 5-10 years. In children younger than 2 years, most pharyngitis is of viral etiology, although GABHS is responsible in rare instances. Viral pharyngitis occurs in persons of all ages. CLINICALHistory
Physical
Causes
DIFFERENTIALSDiphtheria Mononucleosis and Epstein-Barr Virus Infection Mycoplasma Infections
|
| Drug Name | Amoxicillin (Amoxil, Polymox, Trimox, Pro-Amox, Wymox) |
|---|---|
| Description | Often used in place of penicillin, but it has not been demonstrated to be more effective. Amoxicillin binds to PBPs, inhibiting bacterial cell wall growth. |
| Adult Dose | 250-500 mg PO tid; not to exceed 3 g/d |
| Pediatric Dose | 25-50 mg/kg/d PO divided q8h for 10 d >2 years: Recent study showed that 750 mg/d PO for 10 d was as effective as 250 mg PO tid |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces efficacy of PO contraceptives; increased serum concentration with coadministration of probenecid |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in documented hypersensitivity to cephalosporin; caution in renal dysfunction (consider dosage modification), consider consultation with a nephrologist; increased risk of maculopapular rash with EBV, acute lymphocytic leukemia, and CMV |
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Binds to the 50S ribosomal subunit of the bacteria, inhibiting protein synthesis. |
| Adult Dose | 500 mg PO on day 1, followed by 250 mg PO on days 2-5 |
| Pediatric Dose | 12 mg/kg/d PO for 5 d; not to exceed 500 mg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Limited studies have examined possible interactions; possible interaction with drugs that interact with erythromycin (eg, theophylline, digoxin, anticoagulants); do not administer with antacids |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Patients who have an allergic reaction to azithromycin need a longer-than-usual observation period given the medication's long half-life; caution in impaired liver function; possible adverse drug reactions with GI symptoms (eg, diarrhea, abdominal pain, nausea, vomiting) |
| Drug Name | Benzathine penicillin G (Bicillin L-A) |
|---|---|
| Description | Has been shown to be effective in more than 90% of cases. Penicillin binds to PBPs, inhibiting bacterial cell wall growth. |
| Adult Dose | 1.2 million U IM as a single dose |
| Pediatric Dose | 25,000-50,000 U/kg IM as a single dose; not to exceed 1.2 million U <27.3 kg: 300,000-600,000 U IM as a single dose >27.3 kg: 900,000-1,200,000 U IM as a single dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Increased serum concentration with probenecid |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in impaired renal function; for deep IM administration only; do not administer IV, SQ, or intra-arterially |
| Drug Name | Penicillin VK (Pen VK, Pen-Vee K, Veetids) |
|---|---|
| Description | DOC for patients who can tolerate PO therapy. Inhibits the biosynthesis of cell wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations are reached, and most effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. |
| Adult Dose | 250 mg PO tid/qid for 10 d |
| Pediatric Dose | <27.3 kg: 125 mg PO tid/qid for 10 d >27.3 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Increased serum concentrations with probenecid |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in cephalosporin allergies and renal impairment; administer 1 h ac or 2 h pc |
| Drug Name | Erythromycin ethyl succinate (E.E.S, EryPed) |
|---|---|
| Description | Recommended by the AAP for patients who are allergic to penicillin. Erythromycin binds to the 50S ribosomal subunit of the bacteria, inhibiting protein synthesis. |
| Adult Dose | 400-800 mg (as the ethylsuccinate salt) PO qid |
| Pediatric Dose | 40 mg/kg/d PO divided tid/qid for 10 d |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Potent inhibitor of CYP450 3A4; coadministration may increase toxicity of CYP450 3A4 substrates (eg, theophylline, digoxin, carbamazepine, cyclosporine); may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin, increases risk of rhabdomyolysis; decreases metabolism of repaglinide, thus increasing serum levels and effects |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in hepatic impairment; commonly causes GI symptoms (eg, abdominal pain, diarrhea, nausea, vomiting) |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Can be used for recurrent GABHS pharyngitis or in carrier-state cases. Inhibits bacterial protein synthesis by its action at the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Some prefer this medication when treating disease related to peritonsillar abscesses that have been drained. |
| Adult Dose | 150-300 mg PO tid |
| Pediatric Dose | 30 mg/kg/d PO divided tid for 10 d; not to exceed 1.8 g/d |
| Contraindications | Documented hypersensitivity; hepatic impairment prior pseudomembranous colitis |
| Interactions | Increased neuromuscular block with coadministration of pancuronium and tubocurarine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Renal or hepatic impairment; may cause pseudomembranous colitis; administer cap with full glass of water |
| Drug Name | Rifampin (Rifadin, Rimactane) |
|---|---|
| Description | Recommended in conjunction with penicillin for recurrent GABHS and for carrier states. Inhibits RNA synthesis in bacteria by binding to beta subunit of DNA-dependent RNA polymerase, which, in turn, blocks RNA transcription. |
| Adult Dose | 10 mg/kg/d PO as a single dose; not to exceed 600 mg/d |
| Pediatric Dose | Used in conjunction with penicillin VK for 10 d, 20 mg/kg/d PO divided qid for the last 4 d Alternately, 10 mg/kg PO q12h for 4 d in conjunction with benzathine penicillin |
| Contraindications | Documented hypersensitivity |
| Interactions | Induces microsomal enzymes, which may decrease effects of acetaminophen, PO anticoagulants, barbiturates, benzodiazepines, beta-blockers, chloramphenicol, PO contraceptives, corticosteroids, mexiletine, cyclosporine, digitoxin, disopyramide, estrogens, hydantoins, methadone, clofibrate, quinidine, dapsone, tazobactam, sulfonylureas, theophyllines, tocainide, and digoxin; blood pressure may increase with coadministration of enalapril; coadministration with isoniazid or pyrazinamide may result in higher rate of hepatotoxicity than with either agent alone (discontinue one or both agents if alterations in LFT results occur) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Hepatic impairment; monitor for any severe flulike symptoms; administer on an empty stomach; may discolor urine, tears, sweat, or other body fluids |
| Drug Name | Cefuroxime (Ceftin) |
|---|---|
| Description | Second-generation cephalosporin that maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis. Resists degradation by beta-lactamase. Very effective against copathogens. A broad variety of cephalosporins (especially second-generation) have been used; however, their ability to prevent rheumatic heart disease is not known. The oral susp and tabs are not bioequivalent and require different dosage regimens. |
| Adult Dose | 250-500 mg PO bid |
| Pediatric Dose | Susp: 20 mg/kg/d PO divided bid; not to exceed 500 mg/d Tab: 125 mg PO bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h after administration; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics (eg, loop diuretics); coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Administer one-half dose if CrCl is 10-30 mL/min and one-fourth dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin with broad-spectrum gram-negative activity. Arrests bacterial growth by binding to one or more penicillin-binding proteins. |
| Adult Dose | 1-2 g/d IM for 10 d |
| Pediatric Dose | 50 mg/kg/d IM for 10 d; not to exceed 1 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in breastfeeding women and those who are allergic to penicillin; adjust dose in renal impairment |
| Drug Name | Cefditoren (Spectracef) |
|---|---|
| Description | Semisynthetic cephalosporin administered as prodrug. Hydrolyzed by esterases during absorption and distributed in circulating blood as active cefditoren. Bactericidal activity results from inhibition of cell wall synthesis via affinity for penicillin-binding proteins. No dose adjustment necessary for mild renal impairment (CrCl 50-80 mgL/min/1.73 m2) or mild-to-moderate hepatic impairment. Indicated for the treatment of acute exacerbation of pharyngitis/tonsillitis caused by susceptible strains of Streptococcus pyogenes. |
| Adult Dose | 200 mg PO bid pc for 10 d |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults Severe renal impairment (ie, CrCl <30 mL/min/1.73 m2): Decrease dose to 200 mg PO qd |
| Contraindications | Documented hypersensitivity to drug, penicillin, related compounds, or milk protein sodium caseinate; carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency |
| Interactions | Absorption reduced with H2-receptor antagonists and magnesium and aluminum hydroxide antacids may reduce absorption; probenecid may increase plasma concentrations |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May cause diarrhea, nausea, and vaginal moniliasis (yeast infection); pseudomembranous colitis may occur; clinical manifestations of carnitine deficiency may occur with prolonged use; prolonged use may result in emergence and overgrowth of resistant organisms; caution in breastfeeding |
These agents may be used adjunctively to antibiotics to improve pain relief onset and are especially useful in patients with positive rapid streptococcal antigen test results.
| Drug Name | Dexamethasone (Decadron, Dexasone) |
|---|---|
| Description | Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reducing capillary permeability. Possesses many pharmacologic benefits but also significant adverse effects. Stabilizes cell and lysosomal membranes, increases surfactant synthesis, increases serum vitamin A concentration, and inhibits prostaglandin and proinflammatory cytokines (eg, TNF-alpha, IL-6, IL-2, and IFN-gamma). The inhibition of chemotactic factors and factors that increase capillary permeability inhibits recruitment of inflammatory cells into affected areas. Suppresses lymphocyte proliferation through direct cytolysis and inhibits mitosis. Breaks down granulocyte aggregates and improves pulmonary microcirculation. Readily absorbed via the GI tract and metabolized in the liver. Inactive metabolites are excreted via the kidneys. Lacks salt-retaining property of hydrocortisone. Patients can be switched from an IV to PO regimen in a 1:1 ratio. For pharyngitis, corticosteroids must be administered in conjunction with antibiotics. Provides symptomatic relief for severe pharyngitis. A one-time IM dose is convenient and avoids compliance issues. |
| Adult Dose | 0.75-9 mg/d PO/IM/IV in divided doses q6-12h |
| Pediatric Dose | 0.6 mg/kg PO once; if multiple doses used, not to exceed 10 mg/m2/d divided q6-12h |
| Contraindications | Documented hypersensitivity; active bacterial or fungal infection |
| Interactions | Effects decrease with coadministration of barbiturates, phenytoin, and rifampin; decreases effect of salicylates and vaccines used for immunization |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Most adverse effects of corticosteroids are dose-dependent or duration-dependent; increases risk of multiple complications, including severe infections; monitor adrenal insufficiency when tapering drug; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications of glucocorticoid use |
Article Last Updated: Nov 24, 2008